Propranolol does not reduce risk for acute stress disorder in pediatric burn trauma.

Sherri Sharp, Christopher Thomas, Laura Rosenberg, Marta Rosenberg, Walter Meyer

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: Acute stress disorder (ASD) can interfere with satisfactory recovery of children with severe burn injuries. Recent studies have found propranolol to be effective in reducing posttraumatic symptoms, but the benefits of this medication with ASD are unknown. Therefore, we hypothesized that individuals who were administered propranolol acutely would be less likely to develop ASD than those who were not. METHOD: A review of electronic medical records was conducted on the children included in a previous blinded randomized-control trial, in which the participants received propranolol or no propranolol during the acute phase of recovery (first 30 days). These data were merged with electronic information regarding medication treatment for ASD. The psychologists and clinicians who had previously assessed for ASD for purposes of treating the children's distress were blinded to who received propranolol and who did not. RESULTS: There were 363 participants (232 boys, 131 girls) and the mean total body surface area was 56%. Of this sample, 22 participants had been previously diagnosed and treated for ASD, and 341 were in a non-ASD group. Eight percent of those children who received propranolol required treatment for ASD, whereas 5% of children who received no propranolol also required treatment for ASD. No statistically significant difference was noted. CONCLUSIONS: Propranolol was not found to influence the risk for subsequent ASD. This finding is in contrast to the observed benefit of propranolol reported in other studies with different at risk populations. Further exploration is warranted to assess the possible long-term benefit on posttraumatic symptoms in pediatric burn survivor patients.

Original languageEnglish (US)
Pages (from-to)193-197
Number of pages5
JournalThe Journal of trauma
Volume68
Issue number1
StatePublished - Jan 2010
Externally publishedYes

Fingerprint

Stress Disorders, Traumatic, Acute
Propranolol
Pediatrics
Wounds and Injuries
Electronic Health Records
Body Surface Area
Survivors
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sharp, S., Thomas, C., Rosenberg, L., Rosenberg, M., & Meyer, W. (2010). Propranolol does not reduce risk for acute stress disorder in pediatric burn trauma. The Journal of trauma, 68(1), 193-197.

Propranolol does not reduce risk for acute stress disorder in pediatric burn trauma. / Sharp, Sherri; Thomas, Christopher; Rosenberg, Laura; Rosenberg, Marta; Meyer, Walter.

In: The Journal of trauma, Vol. 68, No. 1, 01.2010, p. 193-197.

Research output: Contribution to journalArticle

Sharp, S, Thomas, C, Rosenberg, L, Rosenberg, M & Meyer, W 2010, 'Propranolol does not reduce risk for acute stress disorder in pediatric burn trauma.', The Journal of trauma, vol. 68, no. 1, pp. 193-197.
Sharp, Sherri ; Thomas, Christopher ; Rosenberg, Laura ; Rosenberg, Marta ; Meyer, Walter. / Propranolol does not reduce risk for acute stress disorder in pediatric burn trauma. In: The Journal of trauma. 2010 ; Vol. 68, No. 1. pp. 193-197.
@article{15cdc5a26ba3485d8c20a4b53caabf30,
title = "Propranolol does not reduce risk for acute stress disorder in pediatric burn trauma.",
abstract = "OBJECTIVE: Acute stress disorder (ASD) can interfere with satisfactory recovery of children with severe burn injuries. Recent studies have found propranolol to be effective in reducing posttraumatic symptoms, but the benefits of this medication with ASD are unknown. Therefore, we hypothesized that individuals who were administered propranolol acutely would be less likely to develop ASD than those who were not. METHOD: A review of electronic medical records was conducted on the children included in a previous blinded randomized-control trial, in which the participants received propranolol or no propranolol during the acute phase of recovery (first 30 days). These data were merged with electronic information regarding medication treatment for ASD. The psychologists and clinicians who had previously assessed for ASD for purposes of treating the children's distress were blinded to who received propranolol and who did not. RESULTS: There were 363 participants (232 boys, 131 girls) and the mean total body surface area was 56{\%}. Of this sample, 22 participants had been previously diagnosed and treated for ASD, and 341 were in a non-ASD group. Eight percent of those children who received propranolol required treatment for ASD, whereas 5{\%} of children who received no propranolol also required treatment for ASD. No statistically significant difference was noted. CONCLUSIONS: Propranolol was not found to influence the risk for subsequent ASD. This finding is in contrast to the observed benefit of propranolol reported in other studies with different at risk populations. Further exploration is warranted to assess the possible long-term benefit on posttraumatic symptoms in pediatric burn survivor patients.",
author = "Sherri Sharp and Christopher Thomas and Laura Rosenberg and Marta Rosenberg and Walter Meyer",
year = "2010",
month = "1",
language = "English (US)",
volume = "68",
pages = "193--197",
journal = "Journal of Trauma and Acute Care Surgery",
issn = "2163-0755",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Propranolol does not reduce risk for acute stress disorder in pediatric burn trauma.

AU - Sharp, Sherri

AU - Thomas, Christopher

AU - Rosenberg, Laura

AU - Rosenberg, Marta

AU - Meyer, Walter

PY - 2010/1

Y1 - 2010/1

N2 - OBJECTIVE: Acute stress disorder (ASD) can interfere with satisfactory recovery of children with severe burn injuries. Recent studies have found propranolol to be effective in reducing posttraumatic symptoms, but the benefits of this medication with ASD are unknown. Therefore, we hypothesized that individuals who were administered propranolol acutely would be less likely to develop ASD than those who were not. METHOD: A review of electronic medical records was conducted on the children included in a previous blinded randomized-control trial, in which the participants received propranolol or no propranolol during the acute phase of recovery (first 30 days). These data were merged with electronic information regarding medication treatment for ASD. The psychologists and clinicians who had previously assessed for ASD for purposes of treating the children's distress were blinded to who received propranolol and who did not. RESULTS: There were 363 participants (232 boys, 131 girls) and the mean total body surface area was 56%. Of this sample, 22 participants had been previously diagnosed and treated for ASD, and 341 were in a non-ASD group. Eight percent of those children who received propranolol required treatment for ASD, whereas 5% of children who received no propranolol also required treatment for ASD. No statistically significant difference was noted. CONCLUSIONS: Propranolol was not found to influence the risk for subsequent ASD. This finding is in contrast to the observed benefit of propranolol reported in other studies with different at risk populations. Further exploration is warranted to assess the possible long-term benefit on posttraumatic symptoms in pediatric burn survivor patients.

AB - OBJECTIVE: Acute stress disorder (ASD) can interfere with satisfactory recovery of children with severe burn injuries. Recent studies have found propranolol to be effective in reducing posttraumatic symptoms, but the benefits of this medication with ASD are unknown. Therefore, we hypothesized that individuals who were administered propranolol acutely would be less likely to develop ASD than those who were not. METHOD: A review of electronic medical records was conducted on the children included in a previous blinded randomized-control trial, in which the participants received propranolol or no propranolol during the acute phase of recovery (first 30 days). These data were merged with electronic information regarding medication treatment for ASD. The psychologists and clinicians who had previously assessed for ASD for purposes of treating the children's distress were blinded to who received propranolol and who did not. RESULTS: There were 363 participants (232 boys, 131 girls) and the mean total body surface area was 56%. Of this sample, 22 participants had been previously diagnosed and treated for ASD, and 341 were in a non-ASD group. Eight percent of those children who received propranolol required treatment for ASD, whereas 5% of children who received no propranolol also required treatment for ASD. No statistically significant difference was noted. CONCLUSIONS: Propranolol was not found to influence the risk for subsequent ASD. This finding is in contrast to the observed benefit of propranolol reported in other studies with different at risk populations. Further exploration is warranted to assess the possible long-term benefit on posttraumatic symptoms in pediatric burn survivor patients.

UR - http://www.scopus.com/inward/record.url?scp=75649129706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75649129706&partnerID=8YFLogxK

M3 - Article

VL - 68

SP - 193

EP - 197

JO - Journal of Trauma and Acute Care Surgery

JF - Journal of Trauma and Acute Care Surgery

SN - 2163-0755

IS - 1

ER -